Rhodri M. L. Morgan

The paper identifies a macrocyclic peptide binder, IMP2660, that disrupts RAB27A-effector interactions and enables crystallization of RAB27A without an effector, revealing its structural features.

This paper develops the first cell-active covalent inhibitors of RAB27-effector interactions, showing enantioselectivity and improved potency over a previously reported toxic compound.

The paper demonstrates a method to generate diverse halogenated and derivatized analogues of the natural product violacein using synthetic biology and chemistry.